Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 9, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 800,000 ordinary shares.
- Purchase Price: 1,225.97 pence per share.
- Total Transaction Value: Approximately 980,776 GBP (calculated from disclosed figures).
Material Changes
Following the repurchase and subsequent cancellation of the 800,000 shares:
- Treasury Shares: The company holds 474,194,158 shares in Treasury, representing 9.13% of total voting rights.
- Shares in Issue: There are 5,194,593,100 shares in issue (excluding Treasury shares), which constitutes the total voting rights for disclosure purposes.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming the execution of a share buyback authorized by shareholders at the Annual General Meeting on May 21, 2008.
Investor Verification Checklist
- Verify the total number of shares in issue (5,194,593,100) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on the 9.13% voting rights representation.
- Note that this filing does not contain operational or financial performance data for the period; refer to Form 20-F for full financial results.